Pyrazinamide description: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
Gerald Chi (talk | contribs) mNo edit summary |
||
| (One intermediate revision by one other user not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Pyrazinamide }} | {{Pyrazinamide}} | ||
{{CMG}}; {{AE}} {{chetan}} | {{CMG}}; {{AE}} {{chetan}} | ||
| Line 13: | Line 13: | ||
|} | |} | ||
Each Pyrazinamide tablet for oral administration contains 500 mg of pyrazinamide and the following inactive ingredients: dibasic calcium phosphate (dihydrate), colloidal silicon dioxide, croscarmellose sodium, microcrystalline cellulose, and stearic acid.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = PYRAZINAMIDE (PYRAZINAMIDE) TABLET [MIKART, INC.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a719ec72-771f-49c9-b93d-9d5f585176a4 | publisher = | date = | accessdate = }}</ref> | |||
==References== | |||
{{Reflist}} | {{Reflist}} | ||
Latest revision as of 02:55, 4 January 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Chetan Lokhande, M.B.B.S [2]
Description
Pyrazinamide, the pyrazine analogue of nicotinamide, is an antituberculous agent. It is a white crystalline powder, stable at room temperature, and sparingly soluble in water. Pyrazinamide has the following structural formula:
 |
Each Pyrazinamide tablet for oral administration contains 500 mg of pyrazinamide and the following inactive ingredients: dibasic calcium phosphate (dihydrate), colloidal silicon dioxide, croscarmellose sodium, microcrystalline cellulose, and stearic acid.[1]
References
Adapted from the FDA Package Insert.